Form D · Biotechnology

IconOVir Bio, Inc.

New York, NY · CIK 0001834886

Offering snapshot reported Jun 4, 2024 · SEC filing

Reported sold: $20.2M
Investors reported: 34
Minimum accepted: $0
First sale: Jun 6, 2023

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jun 4, 2024	Amendment	$20,230,000	$0vs Jun 21, 2023	34	SEC filing
Jun 21, 2023	Initial	$20,230,000	No comparison	34	SEC filing
Dec 14, 2020	Initial	$76,998,631	No comparison	47	SEC filing

Offering details

Securities: Debt, Security to be acquired
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-484703

Source: Form D, filed Jun 4, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Sean Algeo	Executive, Promoter
Arie S. Belldegrun	Director, Promoter
David Chang	Director, Promoter
John Huynh	Executive
William Kaelin	Director
Joshua Kazam	Director, Promoter
Helen S. Kim	Director
Jakob Loven	Director
Julie Maltzman	Executive
Mark A. Mc Camish	Director, Executive
Heba Nowyhed	Executive
David M. Tanen	Executive, Promoter
Nicole Van De Leuv	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

689 Fifth Avenue 12th Floor
New York, NY, 10022